Literature DB >> 29877205

Adipokine and cytokine levels in non-functioning adrenal incidentalomas (NFAI).

Anna Babinska1, Mariusz Kaszubowski2, Krzysztof Sworczak1.   

Abstract

Due to the fact that overweight or obesity is accompanied by hormonally active adrenal tumors: Cushing Syndrome-(CS) and Subclinical Cushing Syndrome (SCS), it is of high interest the correlation between different adipokines and cytokines secreted by adipose tissue, with metabolic disorders and hormonal activity in this group. Even in non-functioning adrenal incidentalomas (NFAI) elevated risk for cardiovascular disease and metabolic syndrome was demonstrated. The aim of the study was to investigate plasma adiponectin, leptin, resistin, tumor necrosis factor α (TNFα), interleukin 6 (IL6) and monocyte chemoattractant protein 1 (MCP1) levels in patients with NFAIs and healthy subjects. The study included 18 NFAI patients and 18 healthy subjects. The groups were homogeneous in terms of age, sex and body mass index (BMI). Patients with NFAI showed significantly higher circulating levels of pro-inflammatory cytokines compared to healthy controls (MCP 1: p < 0.001; TNFα p = 0.021; IL6 p = 0.012). On the other hand, adiponectin concentration was significantly lower in the NFAI group (p = 0.034). The serum leptin and resistin concentrations did not differ significantly between the two groups. Acquired results were not dependent on glucocorticoid and catecholamine secretion in NFAI patients. Also, there were no clear correlations between BMI and cytokine levels. It is possible that increased risk for cardiovascular and metabolic diseases reported in NFAI patients is at least partially dependent on adipose tissue activity.

Entities:  

Keywords:  Adipokines; Adrenal tumors; Cytokines

Mesh:

Substances:

Year:  2018        PMID: 29877205     DOI: 10.1507/endocrj.EJ18-0066

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  5 in total

1.  NEW BIOMARKERS TO PREDICT CARDIOVASCULAR RISK IN PATIENTS WITH ADRENAL INCIDENTALOMA; IRISIN AND NESFATIN-1.

Authors:  M Can; M Kocabaş; M Karaköse; Y Alsancak; F H Yerlikaya; H Caliskan Burgucu; I Cordan; C Kadiyoran; M Kulaksızoğlu; F Karakurt
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Apr-Jun       Impact factor: 1.104

2.  Cross-Talk Between Nitrosative Stress, Inflammation and Hypoxia-Inducible Factor in Patients with Adrenal Masses.

Authors:  Barbara Choromańska; Piotr Myśliwiec; Tomasz Kozłowski; Magdalena Łuba; Piotr Wojskowicz; Jacek Dadan; Hanna Myśliwiec; Katarzyna Choromańska; Katarzyna Makarewicz; Anna Zalewska; Mateusz Maciejczyk
Journal:  J Inflamm Res       Date:  2021-11-30

3.  A retrospective study on the association between urine metanephrines and cardiometabolic risk in patients with nonfunctioning adrenal incidentaloma.

Authors:  Mirko Parasiliti-Caprino; Chiara Lopez; Martina Bollati; Fabio Bioletto; Chiara Sola; Maria Chiara Di Carlo; Federico Ponzetto; Iacopo Gesmundo; Fabio Settanni; Ezio Ghigo; Giulio Mengozzi; Mauro Maccario; Roberta Giordano
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

4.  Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors.

Authors:  Nadia Sawicka-Gutaj; Hanna Komarowska; Dawid Gruszczyński; Aleksandra Derwich; Anna Klimont; Marek Ruchała
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

Review 5.  Novel insights into the pathological mechanisms of metabolic related dyslipidemia.

Authors:  Xin Su; Ye Cheng; Guoming Zhang; Bin Wang
Journal:  Mol Biol Rep       Date:  2021-07-04       Impact factor: 2.316

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.